» Articles » PMID: 29589479

Magnetically Assisted Intraperitoneal Drug Delivery for Cancer Chemotherapy

Overview
Journal Drug Deliv
Specialty Pharmacology
Date 2018 Mar 29
PMID 29589479
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Intraperitoneal (IP) chemotherapy has revived hopes during the past few years for the management of peritoneal disseminations of digestive and gynecological cancers. Nevertheless, a poor drug penetration is one key drawback of IP chemotherapy since peritoneal neoplasms are notoriously resistant to drug penetration. Recent preclinical studies have focused on targeting the aberrant tumor microenvironment to improve intratumoral drug transport. However, tumor stroma targeting therapies have limited therapeutic windows and show variable outcomes across different cohort of patients. Therefore, the development of new strategies for improving the efficacy of IP chemotherapy is a certain need. In this work, we propose a new magnetically assisted strategy to elevate drug penetration into peritoneal tumor nodules and improve IP chemotherapy. A computational model was developed to assess the feasibility and predictability of the proposed active drug delivery method. The key tumor pathophysiology, including a spatially heterogeneous construct of leaky vasculature, nonfunctional lymphatics, and dense extracellular matrix (ECM), was reconstructed in silico. The transport of intraperitoneally injected magnetic nanoparticles (MNPs) inside tumors was simulated and compared with the transport of free cytotoxic agents. Our results on magnetically assisted delivery showed an order of magnitude increase in the final intratumoral concentration of drug-coated MNPs with respect to free cytotoxic agents. The intermediate MNPs with the radius range of 200-300 nm yield optimal magnetic drug targeting (MDT) performance in 5-10 mm tumors while the MDT performance remains essentially the same over a large particle radius range of 100-500 nm for a 1 mm radius small tumor. The success of MDT in larger tumors (5-10 mm in radius) was found to be markedly dependent on the choice of magnet strength and tumor-magnet distance while these two parameters were less of a concern in small tumors. We also validated in silico results against experimental results related to tumor interstitial hypertension, conventional IP chemoperfusion, and magnetically actuated movement of MNPs in excised tissue.

Citing Articles

Multiphysics analysis of the dual role of magnetoelectric nanoparticles in a microvascular environment: from magnetic targeting to electrical activation.

Lenzuni M, Giannoni P, Chiaramello E, Fiocchi S, Suarato G, Ravazzani P Front Bioeng Biotechnol. 2025; 12():1467328.

PMID: 39840138 PMC: 11747017. DOI: 10.3389/fbioe.2024.1467328.


Application of artificial intelligence in the diagnosis, treatment, and recurrence prediction of peritoneal carcinomatosis.

Wei G, Zhou Y, Li Z, Qiu M Heliyon. 2024; 10(7):e29249.

PMID: 38601686 PMC: 11004411. DOI: 10.1016/j.heliyon.2024.e29249.


Multi-Scale and Multi-Physics Models of the Transport of Therapeutic/Diagnostic Cancer Agents.

Moradi Kashkooli F, Kolios M Cancers (Basel). 2023; 15(24).

PMID: 38136395 PMC: 10741463. DOI: 10.3390/cancers15245850.


An in silico model of the capturing of magnetic nanoparticles in tumour spheroids in the presence of flow.

Wirthl B, Janko C, Lyer S, Schrefler B, Alexiou C, Wall W Biomed Microdevices. 2023; 26(1):1.

PMID: 38008813 PMC: 10678808. DOI: 10.1007/s10544-023-00685-9.


Computational Multi-Scale Modeling of Drug Delivery into an Anti-Angiogenic Therapy-Treated Tumor.

Mohammadi M, Sefidgar M, Aghanajafi C, Kohandel M, Soltani M Cancers (Basel). 2023; 15(22).

PMID: 38001724 PMC: 10670623. DOI: 10.3390/cancers15225464.


References
1.
Stylianopoulos T, Jain R . Combining two strategies to improve perfusion and drug delivery in solid tumors. Proc Natl Acad Sci U S A. 2013; 110(46):18632-7. PMC: 3832007. DOI: 10.1073/pnas.1318415110. View

2.
Heldin C, Rubin K, Pietras K, Ostman A . High interstitial fluid pressure - an obstacle in cancer therapy. Nat Rev Cancer. 2004; 4(10):806-13. DOI: 10.1038/nrc1456. View

3.
Modarres H, Janmaleki M, Novin M, Saliba J, El-Hajj F, RezayatiCharan M . In vitro models and systems for evaluating the dynamics of drug delivery to the healthy and diseased brain. J Control Release. 2018; 273:108-130. DOI: 10.1016/j.jconrel.2018.01.024. View

4.
Baxter L, Jain R . Transport of fluid and macromolecules in tumors. II. Role of heterogeneous perfusion and lymphatics. Microvasc Res. 1990; 40(2):246-63. DOI: 10.1016/0026-2862(90)90023-k. View

5.
Carlier C, Mathys A, De Jaeghere E, Steuperaert M, de Wever O, Ceelen W . Tumour tissue transport after intraperitoneal anticancer drug delivery. Int J Hyperthermia. 2017; 33(5):534-542. DOI: 10.1080/02656736.2017.1312563. View